Top Page
China Isotope & Radiation Corp.
(1763)
China Isotope & Radiation Corp. (1763) vs. iShares MSCI Hong Kong ETF (EWH)
China Isotope & Radiation Corp. Business Overview & Revenue Model
China Isotope & Radiation Corp. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.62B | 7.57B | 6.63B | 6.15B | 5.14B | 4.27B |
| Gross Profit | 3.68B | 3.68B | 3.48B | 3.51B | 3.24B | 2.62B |
| EBITDA | 1.34B | 1.28B | 1.22B | 1.05B | 901.43M | 717.43M |
| Net Income | 424.14M | 406.64M | 370.97M | 392.27M | 335.75M | 213.58M |
Balance Sheet | ||||||
| Total Assets | 15.65B | 14.77B | 13.19B | 11.69B | 10.47B | 9.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.69B | 2.63B | 2.94B | 2.93B | 2.79B | 2.59B |
| Total Debt | 3.02B | 2.57B | 1.70B | 903.86M | 856.63M | 749.64M |
| Total Liabilities | 7.69B | 7.02B | 6.05B | 5.13B | 4.44B | 3.68B |
| Stockholders Equity | 5.08B | 5.01B | 4.69B | 4.47B | 4.18B | 3.89B |
Cash Flow | ||||||
| Free Cash Flow | -766.49M | 142.48M | -812.66M | 328.66M | 366.59M | -118.01M |
| Operating Cash Flow | 14.07M | 142.48M | 84.96M | 862.66M | 794.31M | 291.91M |
| Investing Cash Flow | -347.00M | -564.81M | -429.88M | -506.62M | -907.36M | -423.90M |
| Financing Cash Flow | 608.94M | 499.70M | 484.37M | -291.50M | -97.44M | -156.25M |
China Isotope & Radiation Corp. Technical Analysis
China Isotope & Radiation Corp. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$6.69B | 14.59 | 8.59% | 2.76% | 13.59% | 6.31% | |
69 Neutral | HK$6.49B | 20.29 | 11.24% | 1.25% | 25.18% | 55.79% | |
62 Neutral | HK$10.67B | 26.67 | 8.69% | 0.77% | 14.56% | 61.60% | |
58 Neutral | HK$7.88B | 46.50 | 4.99% | 0.46% | 35.01% | 483.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$2.70B | 509.09 | 0.22% | ― | -4.38% | ― |
China Isotope & Radiation Corp. Corporate Events
China Isotope & Radiation Corporation announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has been recognized as a National-Level Manufacturing Enterprise and awarded the ‘Single-Item Champion in the Pharmaceutical Industry’ for its Urea [13C/14C] Breath Test Kits. This accolade underscores CIRC’s leading position in the breath diagnostic sector and its commitment to innovation and expanding its product offerings to enhance national health defenses.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
CIRC has announced a significant technological breakthrough in the production of carbon isotope products, specifically high-abundance 13CO gas, which is crucial for urea breath tests detecting Helicobacter pylori infections. This advancement positions China among the few countries capable of producing these materials, reducing reliance on imports and enhancing the nation’s research and production capabilities in stable isotope technology. Additionally, CIRC has started phase II construction of its stable isotope base project, which will ensure a stable supply of these materials, contributing to public health improvements and supporting the Healthy China Initiative.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has been recognized for its exemplary ESG practices, receiving the Outstanding China ESG Practice and ESG Pioneers Index (Top 100) awards at the ESG China Innovation Annual Conference 2025. The company’s focus on technological innovation and sustainable development has led to significant advancements in nuclear technology applications, contributing to economic, environmental, and social benefits while supporting China’s health initiatives.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$19.50 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation announced the successful results of its Extraordinary General Meeting (EGM) held on October 17, 2025. Key resolutions approved included the appointment of a domestic auditor for 2025 and the declaration of an interim dividend of RMB0.0807 per share for the first half of 2025. This decision reflects the company’s commitment to shareholder returns and may enhance its market positioning by demonstrating financial stability and operational transparency.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has announced an updated interim dividend for the six months ending June 30, 2025, with a declared dividend of RMB 0.0807 per share. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09528, with the payment date set for December 31, 2025. The announcement includes details on withholding tax rates applicable to non-resident shareholders, which vary based on their country of residence and existing tax treaties with China. This update reflects the company’s commitment to shareholder returns and provides clarity on the financial implications for international investors.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation’s subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has submitted an IND application for its innovative BNCT boron drug, ‘Borofalan (10B) for Injection,’ which has been accepted by the National Medical Products Administration. This development marks a significant breakthrough in China’s BNCT technology, enhancing precision tumor treatment and contributing to global oncology advancements.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has announced the launch of a new isotope separation technology called the ‘Adsorption Trapper’ by its subsidiary, Chengdu Gaotong Isotope Co., Ltd. This innovative technology utilizes fourth-generation MOF materials to enhance nuclear medicine and nuclear fusion development, offering high purity and efficiency at a lower cost. The advancement is expected to significantly impact the national economy by supporting key areas such as nuclear medicine and biomedical research, while also reducing China’s reliance on imported high-end isotopes.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation (CIRC) has signed a Memorandum of Understanding with Brazil’s National Commission for Nuclear Energy to establish a long-term cooperation mechanism. This partnership aims to enhance isotope product supply, quality management, and information exchange, supporting Brazil’s nuclear technology and radiopharmaceutical industries. The agreement is expected to help CIRC expand its international cooperation, promote its technologies, and contribute to the peaceful uses of nuclear technology.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
China Isotope & Radiation Corporation has announced an interim cash dividend of RMB 0.0807 per share for the six months ending June 30, 2025. The announcement includes details about the ex-dividend date, book closure period, and payment date, which are crucial for shareholders to determine their entitlement. This dividend declaration reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor sentiment positively.
China Isotope & Radiation Corporation has announced the postponement of its Extraordinary General Meeting (EGM) originally scheduled for September 17, 2025, now rescheduled to October 17, 2025, due to work arrangements and coordination needs. This delay also affects the payment schedule for the interim dividend for the first half of 2025, which will now be paid by December 31, 2025, instead of the originally planned date in November. These changes may impact shareholder planning and expectations regarding dividend payments.
China Isotope & Radiation Corporation has announced the approval and upcoming launch of its novel Su π one 13C breath analyzer, which has received a Class II medical device registration certificate. This device represents a significant advancement in Helicobacter pylori breath testing technology, offering more reliable and efficient diagnostics. The analyzer reduces testing time from 2 minutes to 30 seconds, enhancing user experience and allowing for broader application in large-scale screening scenarios. This development supports early screening and diagnosis systems for gastric cancer in China, potentially improving healthcare resource utilization.
China Isotope & Radiation Corporation has announced an interim cash dividend of RMB 0.0807 per share for the six months ending June 30, 2025. The dividend will be paid on November 14, 2025, with various withholding tax rates applied depending on the residency status of shareholders, reflecting the company’s commitment to returning value to its investors.
China Isotope & Radiation Corporation has announced its unaudited interim financial results for the first half of 2025, showing comparative figures from the same period in 2024. The publication of these results on both the Stock Exchange and the company’s website highlights CIRC’s commitment to transparency and provides stakeholders with insights into the company’s financial performance and strategic direction.
China Isotope & Radiation Corporation has announced an extraordinary general meeting scheduled for September 17, 2025, to discuss the appointment of a domestic auditor and the approval of an interim dividend of RMB0.0807 per share for the first half of 2025. This meeting is significant for stakeholders as it addresses key financial decisions that could impact the company’s financial health and shareholder returns.
China Isotope & Radiation Corporation announced that its subsidiary, Sichuan CNNC Tongyuan Technology Co., Ltd., has obtained a radiation safety license for its new R&D and production base, the largest in Asia. This development positions CIRC to enhance its production capabilities and expand its market offerings, with plans to introduce new production lines and increase its product portfolio to meet diverse market demands.
China Isotope & Radiation Corporation announced the completion of the transfer registration for a gratuitous transfer of shares by its controlling shareholder, China Baoyuan Investment Co., Ltd., to China National Nuclear Corporation. This transfer involves 108,085,353 domestic shares, representing approximately 33.79% of the company’s total issued share capital. Despite the transfer, China Baoyuan remains the ultimate controlling shareholder, indicating a strategic alignment with China National Nuclear Corporation, potentially strengthening the company’s position in the nuclear technology sector.
China Isotope & Radiation Corporation has announced a board meeting scheduled for August 28, 2025, to discuss and approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and potential returns, impacting investor confidence and market positioning.